<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92885</article-id><article-id pub-id-type="doi">10.7554/eLife.92885</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92885.4</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Chemotherapy activates inflammasomes to cause inflammation-associated bone loss</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-261738"><name><surname>Wang</surname><given-names>Chun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336564"><name><surname>Kaur</surname><given-names>Khushpreet</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336565"><name><surname>Xu</surname><given-names>Canxin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-121859"><name><surname>Abu-Amer</surname><given-names>Yousef</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5890-5086</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-175830"><name><surname>Mbalaviele</surname><given-names>Gabriel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4660-0952</contrib-id><email>gmbalaviele@wustl.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Division of Bone and Mineral Diseases, Washington University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00q1zbc26</institution-id><institution>Aclaris Therapeutics, Inc</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Orthopaedic Surgery, Washington University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03e8tm275</institution-id><institution>Shriners Hospitals for Children</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0243gzr89</institution-id><institution>Max Planck Institute for Biology Tübingen</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0243gzr89</institution-id><institution>Max Planck Institute for Biology Tübingen</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>04</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP92885</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-10-06"><day>06</day><month>10</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-09"><day>09</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.06.561196"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-08"><day>08</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92885.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-08"><day>08</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92885.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-28"><day>28</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92885.3"/></event></pub-history><permissions><copyright-statement>© 2024, Wang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92885-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92885-figures-v1.pdf"/><abstract><p>Chemotherapy is a widely used treatment for a variety of solid and hematological malignancies. Despite its success in improving the survival rate of cancer patients, chemotherapy causes significant toxicity to multiple organs, including the skeleton, but the underlying mechanisms have yet to be elucidated. Using tumor-free mouse models, which are commonly used to assess direct off-target effects of anti-neoplastic therapies, we found that doxorubicin caused massive bone loss in wild-type mice, a phenotype associated with increased number of osteoclasts, leukopenia, elevated serum levels of danger-associated molecular patterns (DAMPs; e.g. cell-free DNA and ATP) and cytokines (e.g. IL-1β and IL-18). Accordingly, doxorubicin activated the absent in melanoma (AIM2) and NLR family pyrin domain containing 3 (NLRP3) inflammasomes in macrophages and neutrophils, causing inflammatory cell death pyroptosis and NETosis, which correlated with its leukopenic effects. Moreover, the effects of this chemotherapeutic agent on cytokine secretion, cell demise, and bone loss were attenuated to various extent in conditions of AIM2 and/or NLRP3 insufficiency. Thus, we found that inflammasomes are key players in bone loss caused by doxorubicin, a finding that may inspire the development of a tailored adjuvant therapy that preserves the quality of this tissue in patients treated with this class of drugs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>chemotherapy</kwd><kwd>doxorubicin</kwd><kwd>bone</kwd><kwd>inflammation</kwd><kwd>inflammasome</kwd><kwd>pyroptosis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>R01-AR072623</award-id><principal-award-recipient><name><surname>Abu-Amer</surname><given-names>Yousef</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>R01-AR082192</award-id><principal-award-recipient><name><surname>Abu-Amer</surname><given-names>Yousef</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011781</institution-id><institution>Shriners Hospitals for Children</institution></institution-wrap></funding-source><award-id>85109</award-id><principal-award-recipient><name><surname>Abu-Amer</surname><given-names>Yousef</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>P30 AR074992</award-id><principal-award-recipient><name><surname>Abu-Amer</surname><given-names>Yousef</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>R01-AR076758</award-id><principal-award-recipient><name><surname>Mbalaviele</surname><given-names>Gabriel</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01-AI161022</award-id><principal-award-recipient><name><surname>Mbalaviele</surname><given-names>Gabriel</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R01 AG077732</award-id><principal-award-recipient><name><surname>Mbalaviele</surname><given-names>Gabriel</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Inflammasome-mediated inflammation is critically involved in bone loss caused by doxorubicin.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The chemotherapeutic drug, doxorubicin, is widely used for the treatment of breast cancer, bladder cancer, lymphomas, and acute lymphocytic leukemia (<xref ref-type="bibr" rid="bib50">Smith et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Jang et al., 2023</xref>; <xref ref-type="bibr" rid="bib26">Geffen and Man, 2002</xref>). Despite its success in improving the survival rate of cancer patients, doxorubicin causes serious adverse effects, including cardiomyopathy, bone marrow suppression, hair loss, and skeletal manifestations (<xref ref-type="bibr" rid="bib12">Cardinale et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Tacar et al., 2013</xref>; <xref ref-type="bibr" rid="bib20">Coleman et al., 2013</xref>). Bone complications include osteoporosis, a metabolic disease that is characterized by decreased bone mass and deteriorated microarchitecture, and associated with increased risks for the development of late fractures, and morbidities in the elderly populations (<xref ref-type="bibr" rid="bib14">Cauley and Lui, 2009</xref>; <xref ref-type="bibr" rid="bib15">Cawthon et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Cawthon et al., 2012</xref>). In fact, it was reported that 20–50% of geriatric patients (≥65 years) with a hip fracture die within 1 year of fracture (<xref ref-type="bibr" rid="bib20">Coleman et al., 2013</xref>). Consistent with the dogma that bone resorption by osteoclasts (OCs) and bone formation by osteoblasts is uncoupled in osteoporotic patients, doxorubicin causes bone loss by promoting osteoclastogenesis while suppressing osteoblastogenesis (<xref ref-type="bibr" rid="bib68">Yao et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Chai et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Rana et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Zhou and Kuai, 2020</xref>). Increased production of senescence-associated secretory phenotype, enhanced generation of reactive oxygen species, and dysregulated autophagy and mitochondrial metabolism are proposed mechanisms of doxorubicin-induced bone pathology (<xref ref-type="bibr" rid="bib68">Yao et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Park et al., 2022</xref>).</p><p>Doxorubicin intercalates into DNA thereby impeding the activity of DNA repair enzymes such as topoisomerase II and impairing DNA replication (<xref ref-type="bibr" rid="bib45">Robson et al., 1987</xref>; <xref ref-type="bibr" rid="bib35">Lawrence, 1988</xref>; <xref ref-type="bibr" rid="bib8">Bonner and Lawrence, 1990</xref>; <xref ref-type="bibr" rid="bib1">Abe et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Tewey et al., 1984</xref>). Defective DNA repair ultimately culminates in genomic instability and cell demise, events that can provoke uncontrollable release of intracellular contents such as DNA and various danger-associated molecular patterns (DAMPs). DNA-enriched entities include neutrophil extracellular traps (NETs), web-like structures in which DNA is decorated with peptides, some of which have anti-microbial and inflammatory properties (<xref ref-type="bibr" rid="bib34">Komada et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Apel et al., 2021</xref>). NETs can also propagate inflammation following their engulfment by phagocytes (<xref ref-type="bibr" rid="bib6">Boccia et al., 2022</xref>; <xref ref-type="bibr" rid="bib5">Blayney and Schwartzberg, 2022</xref>; <xref ref-type="bibr" rid="bib40">Nakazawa et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Jeong et al., 2021</xref>). Since DNA normally resides in the nucleus and mitochondria, its presence in the cytoplasm is detected by DNA sensors, including absent in melanoma 2 (AIM2), and cyclic guanosine monophosphate-adenosine monophosphate synthase, which can trigger immune responses aimed at eliminating the mislocated DNA (<xref ref-type="bibr" rid="bib52">Sun et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Rathinam et al., 2010</xref>). Oxidized DNA and various DAMPs can also be sensed by NLRP3 (<xref ref-type="bibr" rid="bib49">Shimada et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Lu et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Xian et al., 2022</xref>). Upon recognition of DAMPs or pathogen-associated molecular patterns (PAMPs), AIM2 and NLRP3 assemble protein platforms comprising the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) and caspase-1. These protein complexes known as inflammasomes are responsible for the maturation of pro-interleukin-1β (pro-IL-1β) and pro-IL-18 to IL-1β and IL-18, respectively (<xref ref-type="bibr" rid="bib28">Guo et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Sharma and Kanneganti, 2021</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2021</xref>). Inflammasome-comprising caspase-1 also cleaves gasdermin D (GSDMD), generating N-terminal fragments, which form IL-1β- and IL-18-secreting conduits, and cause the inflammatory cell death, pyroptosis (<xref ref-type="bibr" rid="bib28">Guo et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Sharma and Kanneganti, 2021</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2021</xref>). While acute activation of inflammasomes is important for the clearance of the perceived danger and restoration of homeostasis, chronic or excessive stimulation of these safeguard mechanisms can cause disease.</p><p>Inflammasomes are involved in skeletal pathophysiology. Gain-of-function mutations of <italic>NLRP3</italic> cause skeletal abnormalities in humans (<xref ref-type="bibr" rid="bib2">Aksentijevich et al., 2002</xref>; <xref ref-type="bibr" rid="bib24">Feldmann et al., 2002</xref>), which are reproduced to a great extent in knock-in mice expressing NLRP3 harboring mutations found in these patients (<xref ref-type="bibr" rid="bib7">Bonar et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Qu et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Snouwaert et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Wang et al., 2017</xref>). In normal mice, degraded bone matrix components, which are released during bone resorption, promote inflammasome activation and OC differentiation (<xref ref-type="bibr" rid="bib3">Alippe et al., 2017</xref>). Age-associated bone loss has also been linked to chronic low-grade inflammation mediated by the NLRP3 inflammasome (<xref ref-type="bibr" rid="bib69">Youm et al., 2013</xref>). More relevant to this study, radiation, which is also used as an anti-neoplastic therapy, causes bone loss through GSDMD downstream of AIM2 and NLRP3 inflammasomes, but not NLR family caspase recruitment domain containing protein 4 (NLRC4) inflammasome (<xref ref-type="bibr" rid="bib66">Xiao et al., 2020</xref>). Collectively, the bone phenotypes of genetically or pharmacologically activated inflammasome sensors suggest that the fate of bone cells can be influenced by inflammation driven by inflammasomes, which are mainly activated in myeloid cells (<xref ref-type="bibr" rid="bib10">Brydges et al., 2009</xref>; <xref ref-type="bibr" rid="bib38">Meng et al., 2009</xref>). This view provides a strong rationale for exploring the role of inflammasome pathways in bone loss induced by off-target actions of doxorubicin as this agent causes the death of cancer and bystander normal cells, thereby releasing DAMPs such as ATP and DNA, which activate these pathways.</p><p>We used non-tumor-bearing mouse models, which are commonly used to assess off-target outcomes of anti-neoplastic therapies (<xref ref-type="bibr" rid="bib41">Park et al., 2022</xref>; <xref ref-type="bibr" rid="bib9">Borniger et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Harrison et al., 1980</xref>; <xref ref-type="bibr" rid="bib68">Yao et al., 2020</xref>) to study bone adverse effects of doxorubicin. We found that doxorubicin caused massive bone loss in wild-type (WT) mice, a phenotype associated with increased number of OCs, leukopenia, and cytokinemia. These outcomes implicated the AIM2 and NLRP3 inflammasomes as they were attenuated upon genetic inactivation of these sensors. Thus, our results show that inflammasomes are key players in bone loss caused by doxorubicin, a finding that may enable the implementation of novel strategies for chemotherapy-related bone complications.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Doxorubicin causes bone loss</title><p>To determine the effects of doxorubicin on bone mass, femurs of 10-week-old WT female mice were analyzed by VivaCT before (baseline) and 4 weeks after a single intraperitoneal injection of 5 mg/kg doxorubicin or vehicle. Doxorubicin, but not the vehicle, caused bone loss (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–D</xref>). Doxorubicin also caused bone loss in 10-week-old WT male mice, a response that was associated with increased OC number and surface (<xref ref-type="fig" rid="fig1">Figure 1A–E</xref>) and decreased bone formation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). These findings were consistent with the recently reported stimulatory and suppressive effects of this drug on bone resorption and formation in WT female mice, respectively (<xref ref-type="bibr" rid="bib68">Yao et al., 2020</xref>). Since doxorubicin inflicted bone damage independently of the sex, afterward mechanistic studies focused mainly on male mice and revolved around innate immune responses, which regulate OC-mediated bone resorption in pathological conditions.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Doxorubicin causes bone loss in male mice.</title><p>Femurs from WT male mice were analyzed by VivaCT before (baseline) and 4 weeks after a single intraperitoneal injection of 5 mg/kg doxorubicin. Cross sections of 3D reconstructions. Scale bars: 500 μm (<bold>A</bold>), bone parameters (<bold>B</bold>), and femurs from WT male mice (<bold>C–E</bold>) were analyzed 4 weeks after a single intraperitoneal injection of vehicle or doxorubicin. Specimens were stained for tartrate-resistant acidic phosphatase (TRAP) activity. Representative images. Scale bars: 500 μm (<bold>C</bold>), N.Oc/BS (<bold>D</bold>), Oc.S/BS (<bold>E</bold>). N=5 mice/group. Data are mean ± SEM. Student’s t-test was used. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001. BMD, bone mineral density; BV/TV, bone volume/total volume; Dox, doxorubicin; N.Oc/BS, OC number/bone surface; Oc.S/BS, OC surface/bone surface; OC, osteoclast; ns, not significant; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; WT, wild-type.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Micro-computed tomography (µCT) analysis in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Tartrate-resistant acidic phosphatase (TRAP) staining analysis in <xref ref-type="fig" rid="fig1">Figure 1D and E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Doxorubicin causes bone loss in female mice.</title><p>Femurs from 10-week-old WT female (<bold>A, C</bold>) and male (<bold>B, D</bold>) mice were analyzed by VivaCT before (baseline) and 4 weeks after a single i.p. injection of 5 mg/kg doxorubicin (<bold>A–C</bold>) or vehicle (<bold>D</bold>). For dynamic histomorphometry, male mice were i.p. injected with calcein green and 6 days later with alizarin red and were euthanized 2 days after the second injection. The tibias were used for the analysis. Cross sections of 3D reconstructions of trabecular (<bold>A</bold>; scale bars: 200 μm) and trabecular and cortical (<bold>B</bold>; scale bars: 500 μm) bones. Bone parameters (<bold>C, D</bold>). Dynamic bone parameters (<bold>E</bold>; scale bars: 50 μm). Data are mean ± SEM. N=4–5 mice/group. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001. BFR/BS, bone formation rate/bone surface; BMD bone mineral density; BV/TV, bone volume/total volume; MAR, mineral apposition rate; N.Oc/BS, OC number/bone surface; ns, not significant; OC, osteoclast; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Micro-computed tomography (µCT) analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Dynamic bone parameters analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig1-figsupp1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Doxorubicin causes cytokinemia, leukopenia, release of DAMPs, and NETosis in vivo</title><p>Doxorubicin induces inflammatory responses in patients and experimental models (<xref ref-type="bibr" rid="bib64">Wittenburg et al., 2019</xref>). Accordingly, WT mice exposed to doxorubicin for 3 days exhibited higher serum levels of IL-1β, IL-18, IL-6, and TNF-α compared to vehicle-injected counterparts (<xref ref-type="fig" rid="fig2">Figure 2A–D</xref>). Levels of these inflammatory cytokines inversely correlated with the abundance of white blood cells (WBCs; <xref ref-type="fig" rid="fig2">Figure 2E</xref>). While doxorubicin lowered the number of circulating lymphocytes and monocytes, the number of neutrophils, the most abundant immune cells in the blood, increased 2 hr post-drug exposure before progressively returning to baseline levels. Consistent with the leukopenic outcome, levels of ATP, which is released by dead cells, were higher in doxorubicin-treated mice compared to vehicle-treated cohorts (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). To gain further insight into the mechanisms of leukopenia, we focused on neutrophils, the most abundant leukocytes in blood. These cells exhibit morphological changes such as NET extrusion upon exposure to PAMPs or sterile DAMPs, and eventually undergo NETosis (<xref ref-type="bibr" rid="bib34">Komada et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Apel et al., 2021</xref>). To determine the effects of doxorubicin on NET formation, we measured serum levels of NET components in mice treated with vehicle or this drug for 48 hr. We found that doxorubicin induced NET formation as evidenced by increased levels of citrullinated histone 3 (Cit-H3; <xref ref-type="fig" rid="fig2">Figure 2G</xref>), myeloperoxidase (MPO; <xref ref-type="fig" rid="fig2">Figure 2H</xref>), and cell-free DNA (cfDNA) (<xref ref-type="fig" rid="fig2">Figure 2I and J</xref>). Thus, doxorubicin causes cytokinemia, a response that is associated with increased cell death and decreased number of WBCs.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Doxorubicin causes cytokinemia, leukopenia, release of danger-associated molecular patterns (DAMPs), and NETosis in vivo.</title><p>Twelve-week-old WT mice were exposed to a single dose of vehicle or 5 mg/kg doxorubicin. Serum samples were harvested 3 days (<bold>A–D</bold>) or 2 days (<bold>F–J</bold>) later and analyzed by MSD (IL-1β, IL-6, and TNF-α) or ELISA (Cit-H3, IL-18, and MPO). Blood was collected for cell counts at the indicated time-points after a single dose of 5 mg/kg doxorubicin injection (<bold>E</bold>). cfDNA was measured using Qubit (<bold>I</bold>) or SYBR green (<bold>J</bold>). Data are mean ± SEM. N=5–12 mice/group. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001 vs 0 hr; <sup>##</sup>p&lt;0.01 vs 2 or 24 hr. Student’s t-test (<bold>A–D, F–J</bold>) and one-way ANOVA (<bold>E</bold>) were used. cfDNA, cell-free DNA; Cit-H3, citrullinated histone H3; Dox, doxorubicin; IL, interleukin; MPO, myeloperoxidase; WBCs, white blood cells.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Serum samples analysis of inflammatory cytokines, ATP, citrullinated histone 3 (Cit-H3), myeloperoxidase (MPO), and cfDNA in <xref ref-type="fig" rid="fig2">Figure 2A–D and F–J</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Complete blood count in <xref ref-type="fig" rid="fig2">Figure 2E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig2-v1.tif"/></fig></sec><sec id="s2-3"><title>Doxorubicin activates inflammasome-dependent and -independent pathways, and causes macrophage pyroptosis</title><p>The effects of doxorubicin on macrophages have been reported (<xref ref-type="bibr" rid="bib19">Chen et al., 2023</xref>; <xref ref-type="bibr" rid="bib46">Saleh et al., 2021</xref>). To test the hypothesis that these cells were implicated in the inflammatory phenotype of mice treated with doxorubicin, we treated bone marrow-derived macrophages (BMMs) with lipopolysaccharide (LPS) for 3 hr to induce the expression of inflammasome components (<xref ref-type="bibr" rid="bib63">Wang et al., 2021</xref>), then with various concentrations of this drug for 16 hr. Within its reported potent concentrations (1.5–12 µM) (<xref ref-type="bibr" rid="bib46">Saleh et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Eljack et al., 2022</xref>), doxorubicin did not induce IL-1β secretion, but it significantly caused the release of lactate dehydrogenase (LDH; <xref ref-type="fig" rid="fig3">Figure 3A and B</xref>), a marker of cell death as it is released only upon plasma membrane rupture (<xref ref-type="bibr" rid="bib63">Wang et al., 2021</xref>). Since LDH release was not induced by doxorubicin in a dose-dependent manner, this response may be the result of non-selective cytotoxic actions of this drug. By contrast, doxorubicin promoted IL-1β and LDH release by LPS-primed BMMs in a dose-dependent fashion, with the maximal effect on IL-1β secretion achieved at 6 µM (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Unexpectedly, LPS attenuated LDH release induced by low doxorubicin concentrations (1. 5 and 3 µM) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To further gain insight into the mechanism of action of doxorubicin, we measured the levels of ATP, which is released by dead cells and activates multiple pathways, including the NLRP3 inflammasome (<xref ref-type="bibr" rid="bib32">Karmakar et al., 2016</xref>; <xref ref-type="bibr" rid="bib13">Carta et al., 2015</xref>). ATP levels were higher in the supernatants of doxorubicin-treated BMMs compared to controls, a response that was further enhanced by LPS (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Collectively, these results suggest that BMMs underwent pyroptosis in the presence of LPS and doxorubicin, releasing DAMPs such as ATP.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Doxorubicin activates inflammasomes and causes macrophage pyroptosis.</title><p>WT bone marrow-derived macrophages (BMMs) were left untreated or primed with LPS for 3 hr, then treated with various doxorubicin concentrations for 16 hr. IL-1β (<bold>A</bold>), LDH (<bold>B</bold>), and ATP (<bold>C</bold>) in the conditioned media were measured by enzyme linked immunosorbent assay (ELISA), the cytotoxicity detection kit, or ATP detection kit, respectively. WT BMMs from ASC-citrine mice were primed with 100 ng/ml LPS for 3 hr and treated or not with 15 µM nigericin for 30 min or 10 µM doxorubicin for 16 hr (<bold>D–F</bold>). Non-primed cells were also treated with 10 µM doxorubicin for 16 hr (<bold>G</bold>). Scale bars: 50 µm. ASC specks were visualized under fluorescence microscopy and quantified using ImageJ. Quantitative data (<bold>H</bold>). Data are mean ± SEM from experimental triplicates and represent at least two independent experiments. ***p&lt;0.001 vs. untreated- or LPS-treated cultures. One-way ANOVA. ASC, apoptosis-associated speck-like protein containing a CARD; ATP, adenosine triphosphate; Dox, doxorubicin; IL-1β, interleukin-1β; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; WT, wild-type.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>IL-1β, lactate dehydrogenase (LDH), and ATP analysis of bone marrow-derived macrophages (BMMs) supernatant in <xref ref-type="fig" rid="fig3">Figure 3A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>ASC<sup>+</sup> cells analysis in <xref ref-type="fig" rid="fig3">Figure 3H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig3-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig3-v1.tif"/></fig><p>To reinforce the proposition that doxorubicin activates inflammasomes, we assessed the effects of this drug on the formation of ASC specks, a readout of inflammasome-activated states (<xref ref-type="bibr" rid="bib47">SAtutza et al., 2013</xref>). As anticipated, LPS induced ASC speck formation only in the presence of nigericin, a well-known trigger of NLRP3 inflammasome assembly signals (<xref ref-type="fig" rid="fig3">Figure 3D, E, and H</xref>). Likewise, doxorubicin induced ASC speck formation only in LPS-primed BMMs (<xref ref-type="fig" rid="fig3">Figure 3F, G, and H</xref>). Next, we performed immunoblotting to analyze the expression of NLRP3 and AIM2 since these sensors assemble inflammasomes in response to DAMPs such as ATP and DNA, which were released by doxorubicin-damaged cells. We also determined the expression of other key components of these pathways such as caspase-1 and gasdermins. LPS induced the expression of NLRP3, but not AIM2, caspase-1, caspase-3, GSDMD, and GSDME (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Levels of caspase-1 (p10) and GSDMD (p30) fragments, which are generated upon inflammasome activation, were higher in cells treated with LPS+doxorubicin compared to doxorubicin alone (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). GSDMD (p10) and GSDME (p35) fragments, which are proteolytically generated by caspase-3 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>), were also detected, but their abundance was comparable between cells exposed to LPS+doxorubicin and doxorubicin alone (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Together, these results suggest that doxorubicin activates both caspase-1 and caspase-3, which cleave GSDMD and GSDME, ultimately, causing pyroptosis and IL-1β release.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Doxorubicin activates inflammasome-dependent and -independent pathways in macrophages.</title><p>WT bone marrow-derived macrophages (BMMs) were left untreated or primed with LPS for 3 hr, then treated with various doxorubicin concentrations for 16 hr. Whole cell lysates were analyzed by immunoblotting. Data are representative of at least three independent experiments. AIM2, absent in melanoma 2; cCasp, cleaved caspase; cGSDM, cleaved gasdermin; LPS, lipopolysaccharide; Dox, doxorubicin; WT, wild-type.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (NLRP3).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (AIM2).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (caspase-1).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (cleaved caspase-1).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (caspase-3/cleaved caspase-3).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (gasdermin D [GSDMD]/cleaved GSDMD).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (gasdermin D [GSDMD]/cleaved GSDMD [(p10])).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata8"><label>Figure 4—source data 8.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (GSDME/cleaved GSDME).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data8-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata9"><label>Figure 4—source data 9.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4</xref> (β-actin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data9-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata10"><label>Figure 4—source data 10.</label><caption><title>Original images of the relevant western blot analysis (NLRP3, AIM2, caspase-1/cleaved caspase-1, caspase-3/cleaved caspase-3, gasdermin D [GSDMD]/cleaved GSDMD, GSDME/cleaved GSDME, and β-actin) with highlighted bands and sample labels in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig4-data10-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Cleavage sites of gasdermin D (GSDMD) and GSDME.</title><p>Cleavage sites of murine GSDMD by caspase-1 and caspase-3 (<bold>A</bold>). Cleavage sites of murine GSDME by caspase-3 (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Doxorubicin activates inflammasome-dependent and -independent pathways in macrophages.</title><p>WT bone marrow-derived macrophages (BMMs) were left untreated or primed with lipopolysaccharide (LPS) for 3 hr, then treated with various doxorubicin concentrations for 16 hr. Bar graph represents the quantitative data from whole cell lysates analyzed by immunoblotting.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Western blot analysis of bone marrow-derived macrophages (BMMs) in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig4-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Doxorubicin activates inflammasome-dependent and -independent pathways, and causes NETosis in vitro</title><p>To further support the conclusion that doxorubicin induced the formation of NETs, first, we analyzed the expression of some key players directly or indirectly involved in this process. Incubation of mouse bone marrow neutrophils with LPS resulted in increased NLRP3 expression (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The abundance of caspase-1 (p10) and GSDMD (p30) was indistinguishable between cells exposed to LPS+doxorubicin and doxorubicin alone, likely as the result of cell death as the levels of β-actin used as loading control were markedly reduced in samples from these cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Levels of GSDMD (p10) and GSDME (p35) fragments were also similar between LPS+doxorubicin compared to doxorubicin alone (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). LPS also induced IL-1β secretion, a response that was enhanced by doxorubicin in a dose-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). LPS reduced baseline as well as doxorubicin-induced LDH release (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). In sum, unchallenged neutrophils released LDH, a response that aligned with the presence of functional caspase-3, GSDMD, and GSDME fragments in these cells. However, LPS was required for optimal NLRP3 expression, caspase-1 activation, and IL-1β production by neutrophils. Although neutrophils secreted higher levels of IL-1β in response to doxorubicin, they were highly sensitive to the cytotoxic effects of this drug.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Doxorubicin activates inflammasome-dependent and -independent pathways in neutrophils.</title><p>WT mouse bone marrow neutrophils were left untreated or primed with LPS for 3 hr, then treated with various doxorubicin concentrations for 16 hr. Whole cell lysates were analyzed by immunoblotting. Blots are representative of at least three independent experiments (<bold>A</bold>), IL-1β (<bold>B</bold>), and LDH (<bold>C</bold>) in the conditioned media were measured by enzyme linked immunosorbent assay (ELISA) and the cytotoxicity detection kit, respectively. Data are mean ± SEM from experimental triplicates and are representative of at least two independent experiments. ***p&lt;0.001 vs. LPS; <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001 vs. untreated cultures. One-way ANOVA was used. cCasp, cleaved caspase; cGSDM, cleaved gasdermin; IL-1β, interleukin-1β; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; Dox, doxorubicin.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (NLRP3).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (caspase-1/cleaved caspase-1).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (gasdermin D [GSDMD]/cleaved GSDMD).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig5-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (GSDME/cleaved GSDME).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig5-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (caspase-3/cleaved caspase-3).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig5-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5A</xref> (β-actin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig5-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata7"><label>Figure 5—source data 7.</label><caption><title>Original images for the western blot analysis (NLRP3, caspase-1/cleaved caspase-1, gasdermin D [GSDMD]/cleaved GSDMD, GSDME/cleaved GSDME, caspase-3/cleaved caspase-3, and β-actin) with highlighted bands and sample labels in <xref ref-type="fig" rid="fig5">Figure 5A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92885-fig5-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata8"><label>Figure 5—source data 8.</label><caption><title>IL-1β and lactate dehydrogenase (LDH) analysis of bone marrow neutrophils supernatant in <xref ref-type="fig" rid="fig5">Figure 5B and C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig5-data8-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Doxorubicin activates inflammasome-dependent and -independent pathways in neutrophils.</title><p>Wild-type (WT) neutrophils were left untreated or primed with lipopolysaccharide (LPS) for 3 hr, then treated with various doxorubicin concentrations for 16 hr. Bar graph represents the quantitative data from whole cell lysates analyzed by immunoblotting.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Western blot analysis of bone marrow neutrophils in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Next, we performed immunofluorescence to visualize NET components in neutrophils treated with vehicle or this drug for 16 hr. Consistent with in vivo results, Cit-H3 and MPO were detected in cells treated with doxorubicin but not with vehicle (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Accordingly, levels of cfDNA were higher in doxorubicin-exposed cultures compared to untreated or cultures treated with LPS (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). To determine the biological relevance of cfDNA while modeling the in vivo bone microenvironment, we assessed the impact of degrading cfDNA with DNase I on IL-1β release by cultured whole bone marrow cells, which comprised various cell types, including neutrophils and macrophages. IL-1β levels were higher in cells treated with LPS and doxorubicin compared to LPS, an outcome that was inhibited by DNase I (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Thus, doxorubicin promoted IL-1β release, a response that correlated with its effects on NET formation and abundance of cfDNA.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Doxorubicin causes NETosis in vitro.</title><p>Wild-type (WT) mouse bone marrow neutrophils were left untreated or treated with 10 µM doxorubicin for 16 hr (<bold>A</bold>). Cit-H3 and MPO were analyzed by immunofluorescence. Scale bars: 50 μm. Images are representative of at least three independent experiments. Neutrophils were left untreated or primed with LPS for 3 hr, then treated with 10 µM doxorubicin for 16 hr. cfDNA in the conditioned medium was extracted and quantified (<bold>B</bold>). Neutrophils were left untreated or primed with LPS for 3 hr, then treated with 10 µM doxorubicin and/or DNase I for 16 hr. IL-1β in the conditioned media was measured by enzyme linked immunosorbent assay (ELISA) (<bold>C</bold>). Data are mean ± SEM from experimental triplicates and are representative of at least two independent experiments. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001 vs. LPS; <sup>#</sup>p&lt;0.05, <sup>###</sup>p&lt;0.001 vs. LPS+Dox. One-way ANOVA was used. Dox, doxorubicin; cfDNA, cell-free DNA; Cit-H3, citrullinated histone H3; MPO, myeloperoxidase.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Cell-free DNA (cfDNA) and IL-1β analysis of bone marrow neutrophils supernatant in <xref ref-type="fig" rid="fig6">Figure 6B–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig6-v1.tif"/></fig></sec><sec id="s2-5"><title>AIM2 and NLRP3 inflammasomes are involved in bone-damaging effects of doxorubicin</title><p>We hypothesized that doxorubicin induced IL-1β and IL-18 release by activating the AIM2 and NLRP3 inflammasomes as blood levels of their activators (DNA, ATP) were increased in response to doxorubicin administration (<xref ref-type="fig" rid="fig2">Figure 2F, I, J</xref>). To test this idea, we measured the effects of this drug on IL-1β and LDH release by WT, <italic>Aim2<sup>-/-</sup></italic>, <italic>Nlrp3<sup>-/-</sup></italic>, <italic>Aim2<sup>-/-</sup>; Nlrp3<sup>-/-</sup></italic>, or <italic>Casp1</italic><sup>-/-</sup> BMMs and neutrophils. LPS induction of IL-1β and LDH release by BMMs required doxorubicin, a response that was significantly reduced in <italic>Aim2<sup>-/-</sup></italic> or <italic>Nlrp3<sup>-/-</sup></italic> cells (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). LPS induced IL-1β secretion by neutrophils, an outcome that was enhanced by doxorubicin, and comparably attenuated in all mutants (<xref ref-type="fig" rid="fig7">Figure 7C and D</xref>). Differences in LDH release were marginal, perhaps because baseline levels of this readout were high, consistent with the short lifespan of these cells in vitro. Because inflammation leads to bone loss, we assessed bone outcomes of 10-week-old WT, <italic>Aim2</italic><sup>-/-</sup> and/or <italic>Nlpr3</italic><sup>-/-</sup>, 4 weeks after receiving a single dose of 5 mg/kg doxorubicin or vehicle. Administration of doxorubicin to WT mice caused bone loss associated with increased OC number and surface (<xref ref-type="fig" rid="fig7">Figure 7E–I</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–C</xref>), consistent with the results shown above (<xref ref-type="fig" rid="fig1">Figure 1</xref>). These responses were reduced slightly in <italic>Nlrp3</italic>-deficient mice, but significantly in <italic>Aim2</italic> null mice. <italic>Aim2<sup>-/-</sup></italic> male mice lost bone comparably to <italic>Aim2<sup>-/-</sup>;Nlrp3<sup>-/-</sup></italic> and <italic>casp1<sup>-/-</sup></italic> counterparts (<xref ref-type="fig" rid="fig7">Figure 7E–G</xref>). Similar trends in bone changes were observed in female mice, though <italic>Aim2<sup>-/-</sup></italic> mice were more osteopenic than <italic>casp1<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A–D</xref>). Collectively, our results suggest that the AIM2 and NLRP3 inflammasomes participate to various extent in doxorubicin bone-damaging effects. They also suggest that inflammasome-independent actions of this drug on bone are not negligible.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>AIM2 and NLRP3 inflammasomes are involved in bone-damaging effects of doxorubicin.</title><p>WT, <italic>Aim2<sup>-/-</sup></italic>, <italic>Nlrp3<sup>-/-</sup></italic>, <italic>Aim2<sup>-/-</sup>;Nlrp3<sup>-/-</sup></italic> or <italic>Casp1<sup>-/-</sup></italic> bone marrow-derived macrophages (BMMs) (<bold>A, B</bold>) and neutrophils (<bold>C, D</bold>) were left untreated or primed with LPS for 3 hr, then exposed or not to 10 µM doxorubicin for 16 hr. IL-1β (<bold>A, C</bold>) and LDH (<bold>B, D</bold>) in the conditioned media were measured by enzyme linked immunosorbent assay (ELISA) and the cytotoxicity detection kit, respectively. Femurs from male mice were analyzed by VivaCT before (baseline) and 4 weeks after a single intraperitoneal injection of 5 mg/kg doxorubicin (<bold>E–G</bold>). Cross sections of 3D reconstructions. Scale bars: 500 μm (<bold>E</bold>). BV/TV changes (<bold>F</bold>). BMD changes (<bold>G</bold>). Femurs harvested from different genotypes of male mice were analyzed 4 weeks after a single intraperitoneal injection of vehicle or doxorubicin (<bold>H, I</bold>). Specimens were stained for tartrate-resistant acidic phosphatase (TRAP) activity. N.Oc/BS (<bold>H</bold>). Oc.S/BS (<bold>I</bold>). Data are mean ± SEM from experimental triplicates and are representative of at least two independent experiments (<bold>A–D</bold>); n=5–8 mice/group (<bold>E–I</bold>). Data are mean ± SEM. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001 vs. control, LPS, or vehicle; <sup>##</sup>p&lt;0.01, <sup>###</sup>p&lt;0.001 vs. other genotypes or WT treated with Dox. Two-way ANOVA (<bold>A–D, H–I</bold>) and one-way ANOVA (<bold>F–G</bold>) were used. AIM2, absent in melanoma 2; BMD bone mineral density; BV/TV, bone volume/total volume; casp1, caspase-1; Cont, control; Dox, doxorubicin; IL-1β, interleukin-1β; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; N.Oc/BS, OC number/bone surface; Oc.S/BS; OC, osteoclast; WT, wild-type.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>IL-1β and lactate dehydrogenase (LDH) analysis of different genotypes of bone marrow-derived macrophages (BMMs) and bone marrow neutrophils supernatant in <xref ref-type="fig" rid="fig7">Figure 7A–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig7-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Micro-computed tomography (µCT) analysis of different genotypes of mice in <xref ref-type="fig" rid="fig7">Figure 7F and G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig7-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Tartrate-resistant acidic phosphatase (TRAP) staining analysis of different genotypes of mice in <xref ref-type="fig" rid="fig7">Figure 7H and I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig7-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>AIM2 and NLRP3 inflammasomes are involved in bone-damaging effects of doxorubicin in male mice.</title><p>Femurs from WT, <italic>Aim2<sup>-/-</sup></italic>, <italic>Nlrp3<sup>-/-</sup></italic>, <italic>Aim2<sup>-/-</sup>; Nlrp3<sup>-/-</sup></italic> or <italic>Casp1<sup>-/-</sup></italic> male mice were analyzed by VivaCT before (baseline) and 4 weeks after a single intraperitoneal injection of 5 mg/kg doxorubicin (<bold>A, B</bold>). Cross sections of 3D reconstructions of trabecular and cortical (<bold>A</bold>; scale bars: 500 μm) bones. Bones from WT, <italic>Aim2<sup>-/-</sup></italic>, <italic>Nlrp3<sup>-/-</sup></italic>, <italic>Aim2<sup>-/-</sup>; Nlrp3<sup>-/-</sup></italic> or <italic>Casp1<sup>-/-</sup></italic> male mice were analyzed 4 weeks after a single intraperitoneal injection of vehicle or doxorubicin; specimens were stained for tartrate-resistant acidic phosphatase (TRAP) activity (<bold>C</bold>; scale bars: 400 μm). Data are mean ± SEM. N=5–8 mice/group. ***p&lt;0.001. Two-way ANOVA was used. BV/TV, bone volume/total volume; BMD bone mineral density; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; WT, wild-type.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Micro-computed tomography (µCT) analysis of different genotypes of male mice in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig7-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>AIM2 and NLRP3 inflammasomes are involved in bone-damaging effects of doxorubicin in female mice.</title><p>Femurs from WT, <italic>Aim2<sup>-/-</sup></italic>, <italic>Nlrp3<sup>-/-</sup></italic>, <italic>Aim2<sup>-/-</sup>; Nlrp3<sup>-/-</sup></italic> or <italic>Casp1<sup>-/-</sup></italic> female mice were analyzed by VivaCT before (baseline) and 4 weeks after a single intraperitoneal injection of 5 mg/kg doxorubicin. Cross sections of 3D reconstructions (<bold>A</bold>). BV/TV changes (<bold>B</bold>). BMD changes (<bold>C</bold>). Additional bone parameters (<bold>D</bold>). Data are mean ± SEM. N=5 mice/group. **p&lt;0.01; ***p&lt;0.001; <sup>#</sup>p&lt;0.05; <sup>##</sup>p&lt;0.01; <sup>###</sup>p&lt;0.001. One-way ANOVA (<bold>B, C</bold>) and two-way ANOVA (<bold>D</bold>) were used. Scale bars: 500 μm. BV/TV, bone volume/total volume; BMD bone mineral density; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; WT, wild-type.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Micro-computed tomography (µCT) analysis of different genotypes of female mice in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2B–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92885-fig7-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig7-figsupp2-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We found that the AIM2 inflammasome and the NLRP3 inflammasome to a lesser extent played an important role in bone-damaging effects of doxorubicin. The comparable bone phenotype of <italic>Aim2<sup>-/-</sup>;Nlrp3<sup>-/-</sup></italic> and <italic>casp1<sup>-/-</sup></italic> mice suggested that the AIM2 and NLRP3 inflammasomes were the primary mediators of doxorubicin actions. Because doxorubicin activates several pathways, some of which interact or overlap with inflammasome functions (e.g. senescence factors), the remaining bone loss in compound mutant mice was expected. The interplay among these pathways may have accounted for the sex differences in the bone outcomes of inflammasome insufficiency as residual doxorubicin-induced bone loss was higher in <italic>Aim2<sup>-/-</sup></italic> and <italic>Aim2<sup>-/-</sup>;Nlrp3<sup>-/-</sup></italic> female mice than in male counterparts. Sexual dimorphic actions of inflammasomes were not unprecedented as uneven severity of atherosclerosis was found in male and female <italic>Nlrp3</italic>-deficient mice with gonadal insufficiency (<xref ref-type="bibr" rid="bib18">Chen et al., 2020</xref>) and sex-dependent differential activation of AIM2 and NLRP3 inflammasomes in macrophages from systemic lupus erythematous had been reported (<xref ref-type="bibr" rid="bib67">Yang et al., 2015</xref>). Although the impacts of doxorubicin on bone pathology are complex, including its direct actions on bone cells (<xref ref-type="bibr" rid="bib68">Yao et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Chai et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Rana et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Zhou and Kuai, 2020</xref>), our investigation focused on immune cells, and found that the inactivation of inflammasomes is sufficient to attenuate the drug’s bone-damaging effects.</p><p>Doxorubicin causes neutropenia, lymphopenia, and anemia in patients (<xref ref-type="bibr" rid="bib25">Gatti et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Boccia et al., 2022</xref>). Consistent with the clinical situation, administration of doxorubicin to mice caused leukopenia, which correlated with lymphocytopenia and monocytopenia, and was associated with fluctuations in neutrophil counts. Since neutrophils were highly sensitive to the cytotoxic effects of doxorubicin, the transient neutrophilic effects of this drug in mice may be the result of emergency granulopoiesis, a physiological response that is rapidly triggered to restore adequate neutrophil number. This leukopenic outcome was consistent with increased serum levels of cell death-associated DAMPS (ATP and cfDNA) and our results showing that doxorubicin activated the effectors of apoptosis, pyroptosis, and NETosis, including caspase-1, caspase-3, GSDMD, and GSDME. Since pyroptosis and NETosis promote inflammation and immune responses, we argued that they accounted for the cytokinemic effects of doxorubicin. Other studies, however, found that doxorubicin reduced NET formation in cancer models and by human neutrophils in vitro (<xref ref-type="bibr" rid="bib37">Lu et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Khan et al., 2019</xref>). This discrepancy may be due to differences in the experimental models and cell context-dependent actions of doxorubicin. Other limitations of our study include its focus on: (i) macrophages and neutrophils while oversighting lymphocytes or even other cells bone microenvironment such as mesenchymal and adipocytes whose fate is affected by this drug (<xref ref-type="bibr" rid="bib23">Fan et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Fan et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Wang et al., 2012</xref>; <xref ref-type="bibr" rid="bib11">Buttiglieri et al., 2011</xref>), which were also targeted by doxorubicin; (ii) immune cells without assessing the direct effects of doxorubicin on bone cells, as noted above; and (iii) the use of the tumor-free model as immune responses can differ significantly in the absence or presence of cancer cells. Despite these limitations, our findings point to a novel mechanism of action for doxorubicin in bone.</p><p>DNA accumulates in the cytoplasm as the result of genomic instability, damaged mitochondria, or lysed intracellular pathogens. Extracellular DNA from pathogens, NETotic, or pyroptotic cells can be internalized and culminate in the cytoplasm. In either case, sensors such as AIM2 detect mislocated DNA in the cytoplasm and trigger inflammatory responses (<xref ref-type="bibr" rid="bib6">Boccia et al., 2022</xref>; <xref ref-type="bibr" rid="bib5">Blayney and Schwartzberg, 2022</xref>; <xref ref-type="bibr" rid="bib40">Nakazawa et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Jeong et al., 2021</xref>). This view was consistent with our data showing a correlation between the levels of extracellular DNA and IL-1β as well as by the inhibition of IL-1β secretion by DNase I. We also found that doxorubicin activated the NLRP3 inflammasome and induced the release of ATP, a well-known activator of the NLRP3 inflammasome. Whether doxorubicin activated the NLRP3 inflammasome directly by perturbing the plasma membrane or indirectly via generation of secondary signals such as ATP remained unclear.</p><p>By showing that inflammasomes are key players in bone loss caused by doxorubicin, this work advances our knowledge on potential mechanisms of action of this drug on this tissue (<xref ref-type="fig" rid="fig8">Figure 8</xref>). This insight is difficult to get in clinical situations because this chemotherapeutic is employed not alone but in conjunction with other medications (<xref ref-type="bibr" rid="bib72">Zimny, 1988</xref>; <xref ref-type="bibr" rid="bib54">Svendsen et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Müller et al., 2020</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Graphical abstract.</title><p>Double line arrows: direct effects of doxorubicin on target cells. Solid line arrows: direct contribution to systemic inflammation. Broken line arrows: indirect contribution to systemic inflammation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92885-fig8-v1.tif"/><permissions><copyright-statement>© 2024, BioRender Inc</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>BioRender Inc</copyright-holder><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 8 was created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender</ext-link>, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND</ext-link> license. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>WT<italic>,</italic> R26-CAG-ASC-citrine (030744)<italic>, Aim2<sup>-/-</sup></italic> (013144), and <italic>Nlrp3<sup>-/-</sup></italic> (021302) mice were purchased from The Jackson Laboratory (Sacramento, CA, USA). <italic>Casp1<sup>-/-</sup></italic> were kindly provided by Dr. Thirumala-Devi Kanneganti (St. Jude Children’s Research Hospital). <italic>Aim2<sup>-/-</sup></italic> mice and <italic>Nlrp3<sup>-/-</sup></italic> mice were intercrossed to generate <italic>Aim2<sup>-/-</sup>;Nlrp3<sup>-/-</sup></italic> mice. All mice were on the C57BL/6J background and mouse genotyping was performed by PCR. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Washington University School of Medicine in St. Louis. All experiments were performed in accordance with the relevant guidelines and regulations described in the IACUC-approved protocol 22-0335.</p></sec><sec id="s4-2"><title>Doxorubicin administration and VivaCT analysis</title><p>The femurs of 10-week-old mice were analyzed by VivaCT 2 weeks before (baseline) and 4 weeks after a single intraperitoneal injection (i.p.) of 5 mg/kg doxorubicin (Sigma-Aldrich, MO, USA) formulated in H<sub>2</sub>O at 1 mg/ml or vehicle. For bone analysis, mice were anesthetized with isofluorane and trabecular volume in the distal femoral metaphysis of the right leg was measured using VivaCT 40 (Scanco Medical AG, Zurich, Switzerland) set at 70 kVp, 114 μA, and 20 μm resolution as previously described (<xref ref-type="bibr" rid="bib68">Yao et al., 2020</xref>). For the trabecular bone compartment, contours were traced on the inside of the cortical shell using 2D images of the femoral metaphysis. The end of the growth plate region was used as a landmark to establish a consistent location for starting analysis, and the next 50 slices were analyzed. The following trabecular parameters are reported for all VivaCT experiments: bone volume over total volume, trabecular number, trabecular thickness, trabecular separation, and volumetric bone mineral density.</p></sec><sec id="s4-3"><title>Histomorphometry</title><p>For static histomorphometry, the femurs were fixed in 10% neutral buffered formalin overnight and decalcified in 14% (wt/vol) EDTA, pH 7.2, for 10–14 days at room temperature. Fixed femurs were embedded in paraffin, sectioned at 5 μm thicknesses, and mounted on glass slides. The sections were stained with tartrate-resistant acidic phosphatase as described previously (<xref ref-type="bibr" rid="bib61">Wang et al., 2018</xref>). For dynamic histomorphometry, mice were i.p. injected with 10 mg/kg calcein green (Sigma-Aldrich, MO, USA) and 6 days later with 50 mg/kg alizarin red (Sigma-Aldrich, MO, USA). Mice were euthanized 2 days after the second injection. The tibias were collected and fixed in 10% neutral buffered formalin overnight, embedded in methyl methacrylate, and sectioned at 7–10 μm. Images were taken using a Nanozoomer 2.0 HT whole slide scanner (Hamamatsu Photonics, Shizuoka, Japan) at ×20 magnification. Bioquant Osteo software (v18.2.6; Bioquant Image Analysis Corp, TN, USA) was used for image analysis. Measurements of dynamic bone histomorphometry were calculated from fluorochrome double labels at the endocortical surfaces as previously described (<xref ref-type="bibr" rid="bib66">Xiao et al., 2020</xref>).</p></sec><sec id="s4-4"><title>Serum assays</title><p>Blood was collected by cardiac puncture and was allowed to clot at room temperature. Serum obtained after centrifugation at 2000×<italic>g</italic> for 10 min was used for various assays. Cytokine and chemokine levels were measured by V-PLEX Plus Proinflammatory Panel 1 Mouse Kit (Meso Scale Diagnostics, MD USA), except IL-18, which was analyzed by enzyme linked immunosorbent assay (ELISA) kit (Sigma-Aldrich, MO, USA). The levels of Cit-H3 and MPO were determined by ELISA kits (Abcam, MA, USA, and Cayman, MI, USA).</p></sec><sec id="s4-5"><title>Peripheral blood analysis</title><p>Mouse blood was collected by cardiac puncture in the EDTA-containing tubes. Complete blood counts were performed by the Washington University School of Medicine as previously described (<xref ref-type="bibr" rid="bib60">Wang et al., 2017</xref>).</p></sec><sec id="s4-6"><title>Cell cultures</title><p>Murine primary BMMs were obtained by culturing mouse bone marrow cells in culture media containing a 1:10 dilution of supernatant from the fibroblastic cell line CMG 14-12 as a source of macrophage colony-stimulating factor, a mitogenic factor for BMMs, for 4–5 days in a 15 cm dish as previously described (<xref ref-type="bibr" rid="bib56">Takeshita et al., 2000</xref>; <xref ref-type="bibr" rid="bib62">Wang et al., 2020</xref>). Briefly, nonadherent cells were removed by vigorous washes with PBS, and adherent BMMs were detached with trypsin-EDTA and cultured in culture media containing a 1:10 dilution of CMG for various experiments. Murine primary neutrophils were isolated by collecting bone marrow cells and subsequently over a discontinuous Percoll (Sigma-Aldrich, MO, USA) gradient as described previously (<xref ref-type="bibr" rid="bib53">Sun et al., 2022</xref>). Briefly, all bone marrow cells from femurs and tibias were washed by PBS and then resuspended in 2 ml PBS. Cell suspension was gently layered on top of gradient (72% Percoll, 64% Percoll, 52% Percoll) and centrifuged at 1545×<italic>g</italic> for 30 min at room temperature. After carefully discarding the top two cell layers, the third layer containing neutrophils was transferred to a clean 15 ml tube. Cells were washed and counted, then plated at a density of 1×10<sup>5</sup> cells/well in 96-well plate or 5×10<sup>6</sup> cells/well in six-well plate for 1 hr followed by various experiments. For all in vitro experiments except otherwise specified, BMMs were plated at 2×10<sup>4</sup> cells per well on a 96-well plate or 10<sup>6</sup> cells per well on a six-well plate overnight. Neutrophils were plated at 10<sup>5</sup> cells per well on a 96-well plate or 5×10<sup>6</sup> cells per well on a six-well plate for 1 hr prior to treatment. BMMs and neutrophils were primed with 100 ng/ml LPS (Sigma-Aldrich, MO, USA) for 3 hr, then with different concentrations of doxorubicin (Sigma-Aldrich, MO, USA) as indicated for 16 hr. Conditioned media were collected for the analysis of IL-1β and LDH. Cell lysates were collected for protein expression analysis by western blot as described below.</p></sec><sec id="s4-7"><title>Western blot analysis</title><p>Cell extracts were prepared by lysing cells with RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% NaDOAc, 0.1% SDS, and 1.0% NP-40) plus phosphatase and protease inhibitors (GenDEPOT, TX, USA). Protein concentrations were determined by the Bio-Rad Laboratories method (Bio-Rad, CA, USA), and equal amounts of proteins were subjected to SDS-PAGE gels (12% or 15%) as previously described (<xref ref-type="bibr" rid="bib63">Wang et al., 2021</xref>). Proteins were transferred onto nitrocellulose membranes and incubated with antibodies against GSDMD (1;1000; Abcam, MA, USA; ab219800; ab209845), GSDME (1;1000; Abcam, MA, USA; ab215191), caspase-1 (1;1 000; Abcam, MA, USA; ab179515), caspase-3 (1:1000; Cell Signaling Technologies, MA, USA; 9662S), NLRP3 (1:1000; AdipoGen, CA, USA; AG20B0014C), AIM2 (1:1000; Cell Signaling Technologies, MA, USA; 63660S) or β-actin (1:2000; Santa Cruz Biotechnology, TX, USA; SC47778) overnight at 4°C followed by incubation for 1 hr with secondary goat anti-mouse IRDye 800 (Li-COR Biosciences, NE, USA; 926-32210) or goat anti-rabbit Alexa Fluor 680 (Li-COR Biosciences, NE, USA; 926-68071) respectively. The results were visualized using the Odyssey infrared imaging system (LI-COR Biosciences, NE, USA).</p></sec><sec id="s4-8"><title>LDH assay and IL-1β ELISA</title><p>Cell death was assessed by the release of LDH in conditioned medium using LDH cytotoxicity detection kit (TaKaRa, CA, USA). IL-1β levels in conditioned media were measured by an ELISA kit (eBiosciences, NY, USA).</p></sec><sec id="s4-9"><title>ASC specks assay</title><p>ASC-citrine-WT BMMs were plated at 10<sup>4</sup> cells per well on a 16-well glass plate overnight. Cells were primed with LPS for 3 hr followed by 15 μM nigericin (AdipoGen, CA, USA) for 30 min or the indicated doxorubicin concentrations for 16 hr. Cells were washed with PBS, fixed with 4% paraformaldehyde buffer for 10 min at room temperature, then counterstained with Fluoro-gel II containing DAPI (Fluoro-Gel, Fisher Scientific Intl INC, PA, USA). ASC-citrine photographs were taken using ZEISS microscopy (Carl ZEISS Industrial Metrology, MN, USA). Quantification of ASC specks was carried out using ImageJ.</p></sec><sec id="s4-10"><title>Immunofluorescence</title><p>Isolated neutrophils were plated at 10<sup>5</sup> cells per well on a 16-well glass plate for 1 hr. Cells were primed with LPS for 3 hr, treated with doxorubicin for 16 hr, washed with PBS, and fixed with 4% paraformaldehyde buffer for 10 min at room temperature. Cells were permeabilized with 0.2% Triton in PBS for 20 min, blocked with 0.2% Triton and 1% BSA in PBS for 30 min, and were incubated with Cit-H3 antibody (1:1000; Abcam, MA, USA; ab5103) and MPO (1;1000; Abcam, MA, USA; ab90810) overnight at 4°C in blocking buffer, followed by incubation with secondary antibody (Alexa Fluor 594, 1:2000; Life Technologies, CA, USA; A11020; A27034) for 30 min. Cells were counterstained with Fluoro-gel II containing DAPI (Fluoro-Gel, Fisher Scientific Intl INC, PA, USA). Immunostaining images were taken using a Leica inverted microscope with a TCS SPEII confocal module and processed using LAS X software (Leica Microsystems Inc, IL, USA).</p></sec><sec id="s4-11"><title>cfDNA assay</title><p>cfDNA in the conditioned cell culture medium was extracted using NucleoSpin Gel and PCR Clean-up kit (Takara, Duren, Germany), and quantified with Nanodrop (Thermo Fisher Scientific, MA, USA). cfDNA in the serum was purified and measured using Qubit by Washington University School of Medicine Hope Center DNA/RNA purification Core or using SYBR Green (Thermo Fisher Scientific, MA, USA) as previously described (<xref ref-type="bibr" rid="bib27">Goldshtein et al., 2009</xref>; <xref ref-type="bibr" rid="bib58">Villalba-Campos et al., 2016</xref>).</p></sec><sec id="s4-12"><title>ATP assay</title><p>ATP levels in conditioned media and serum were measured by RealTime-Glo Extracellular ATP Assay kit (Promega, Madison, WI, USA).</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>Statistical analysis was performed using the Student’s t-test, one-way ANOVA with Tukey’s multiple comparisons test, or two-way ANOVA with Tukey’s multiple comparisons test, Dunnett’s multiple comparisons test, or Sidak’s multiple comparisons test using the GraphPad Prism 9.0 software. Values are expressed as mean ± SEM. *p&lt;0.05 was considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Employee of Aclaris Therapeutics, Inc</p></fn><fn fn-type="COI-statement" id="conf3"><p>Holds stocks of Aclaris Therapeutics, Inc</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92885-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided for all figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We want to thank Dr. Deborah J Veis for reading this manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Tadokoro</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>HD</given-names></name><name><surname>Furusawa</surname><given-names>S</given-names></name><name><surname>Tsutsui</surname><given-names>Y</given-names></name><name><surname>Miyake</surname><given-names>R</given-names></name><name><surname>Ishimaru</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Matsushima</surname><given-names>S</given-names></name><name><surname>Koumura</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>K-I</given-names></name><name><surname>Imai</surname><given-names>H</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting alas1-dependent heme synthesis</article-title><source>Science Signaling</source><volume>15</volume><elocation-id>eabn8017</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.abn8017</pub-id><pub-id pub-id-type="pmid">36318618</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksentijevich</surname><given-names>I</given-names></name><name><surname>Nowak</surname><given-names>M</given-names></name><name><surname>Mallah</surname><given-names>M</given-names></name><name><surname>Chae</surname><given-names>JJ</given-names></name><name><surname>Watford</surname><given-names>WT</given-names></name><name><surname>Hofmann</surname><given-names>SR</given-names></name><name><surname>Stein</surname><given-names>L</given-names></name><name><surname>Russo</surname><given-names>R</given-names></name><name><surname>Goldsmith</surname><given-names>D</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Austin</surname><given-names>F</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Balow</surname><given-names>JE</given-names></name><name><surname>Rosenzweig</surname><given-names>S</given-names></name><name><surname>Komarow</surname><given-names>H</given-names></name><name><surname>Shoham</surname><given-names>NG</given-names></name><name><surname>Wood</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Mangra</surname><given-names>N</given-names></name><name><surname>Carrero</surname><given-names>H</given-names></name><name><surname>Adams</surname><given-names>BS</given-names></name><name><surname>Moore</surname><given-names>TL</given-names></name><name><surname>Schikler</surname><given-names>K</given-names></name><name><surname>Hoffman</surname><given-names>H</given-names></name><name><surname>Lovell</surname><given-names>DJ</given-names></name><name><surname>Lipnick</surname><given-names>R</given-names></name><name><surname>Barron</surname><given-names>K</given-names></name><name><surname>O’Shea</surname><given-names>JJ</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases</article-title><source>Arthritis and Rheumatism</source><volume>46</volume><fpage>3340</fpage><lpage>3348</lpage><pub-id pub-id-type="doi">10.1002/art.10688</pub-id><pub-id pub-id-type="pmid">12483741</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alippe</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Ricci</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Novack</surname><given-names>DV</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Civitelli</surname><given-names>R</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bone matrix components activate the NLRP3 inflammasome and promote osteoclast differentiation</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>6630</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-07014-0</pub-id><pub-id pub-id-type="pmid">28747793</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apel</surname><given-names>F</given-names></name><name><surname>Andreeva</surname><given-names>L</given-names></name><name><surname>Knackstedt</surname><given-names>LS</given-names></name><name><surname>Streeck</surname><given-names>R</given-names></name><name><surname>Frese</surname><given-names>CK</given-names></name><name><surname>Goosmann</surname><given-names>C</given-names></name><name><surname>Hopfner</surname><given-names>KP</given-names></name><name><surname>Zychlinsky</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps</article-title><source>Science Signaling</source><volume>14</volume><elocation-id>eaax7942</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aax7942</pub-id><pub-id pub-id-type="pmid">33688080</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blayney</surname><given-names>DW</given-names></name><name><surname>Schwartzberg</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review</article-title><source>Cancer Treatment Reviews</source><volume>109</volume><elocation-id>102427</elocation-id><pub-id pub-id-type="doi">10.1016/j.ctrv.2022.102427</pub-id><pub-id pub-id-type="pmid">35785754</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boccia</surname><given-names>R</given-names></name><name><surname>Glaspy</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><name><surname>Aapro</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Chemotherapy-induced neutropenia and febrile neutropenia in the us: A beast of burden that needs to be tamed?</article-title><source>The Oncologist</source><volume>27</volume><fpage>625</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyac074</pub-id><pub-id pub-id-type="pmid">35552754</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonar</surname><given-names>SL</given-names></name><name><surname>Brydges</surname><given-names>SD</given-names></name><name><surname>Mueller</surname><given-names>JL</given-names></name><name><surname>McGeough</surname><given-names>MD</given-names></name><name><surname>Pena</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Grimston</surname><given-names>SK</given-names></name><name><surname>Hickman-Brecks</surname><given-names>CL</given-names></name><name><surname>Ravindran</surname><given-names>S</given-names></name><name><surname>McAlinden</surname><given-names>A</given-names></name><name><surname>Novack</surname><given-names>DV</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Civitelli</surname><given-names>R</given-names></name><name><surname>Hoffman</surname><given-names>HM</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e35979</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035979</pub-id><pub-id pub-id-type="pmid">22558291</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonner</surname><given-names>JA</given-names></name><name><surname>Lawrence</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Doxorubicin decreases the repair of radiation-induced DNA damage</article-title><source>International Journal of Radiation Biology</source><volume>57</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1080/09553009014550341</pub-id><pub-id pub-id-type="pmid">1967294</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borniger</surname><given-names>JC</given-names></name><name><surname>Gaudier-Diaz</surname><given-names>MM</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>RJ</given-names></name><name><surname>DeVries</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cytotoxic chemotherapy increases sleep and sleep fragmentation in non-tumor-bearing mice</article-title><source>Brain, Behavior, and Immunity</source><volume>47</volume><fpage>218</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2014.11.001</pub-id><pub-id pub-id-type="pmid">25449581</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brydges</surname><given-names>SD</given-names></name><name><surname>Mueller</surname><given-names>JL</given-names></name><name><surname>McGeough</surname><given-names>MD</given-names></name><name><surname>Pena</surname><given-names>CA</given-names></name><name><surname>Misaghi</surname><given-names>A</given-names></name><name><surname>Gandhi</surname><given-names>C</given-names></name><name><surname>Putnam</surname><given-names>CD</given-names></name><name><surname>Boyle</surname><given-names>DL</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name><name><surname>Horner</surname><given-names>AA</given-names></name><name><surname>Soroosh</surname><given-names>P</given-names></name><name><surname>Watford</surname><given-names>WT</given-names></name><name><surname>O’Shea</surname><given-names>JJ</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Hoffman</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity</article-title><source>Immunity</source><volume>30</volume><fpage>875</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.05.005</pub-id><pub-id pub-id-type="pmid">19501000</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttiglieri</surname><given-names>S</given-names></name><name><surname>Ruella</surname><given-names>M</given-names></name><name><surname>Risso</surname><given-names>A</given-names></name><name><surname>Spatola</surname><given-names>T</given-names></name><name><surname>Silengo</surname><given-names>L</given-names></name><name><surname>Avvedimento</surname><given-names>EV</given-names></name><name><surname>Tarella</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The aging effect of chemotherapy on cultured human mesenchymal stem cells</article-title><source>Experimental Hematology</source><volume>39</volume><fpage>1171</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2011.08.009</pub-id><pub-id pub-id-type="pmid">21864489</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardinale</surname><given-names>D</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Bacchiani</surname><given-names>G</given-names></name><name><surname>Tedeschi</surname><given-names>I</given-names></name><name><surname>Meroni</surname><given-names>CA</given-names></name><name><surname>Veglia</surname><given-names>F</given-names></name><name><surname>Civelli</surname><given-names>M</given-names></name><name><surname>Lamantia</surname><given-names>G</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Curigliano</surname><given-names>G</given-names></name><name><surname>Fiorentini</surname><given-names>C</given-names></name><name><surname>Cipolla</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy</article-title><source>Circulation</source><volume>131</volume><fpage>1981</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.013777</pub-id><pub-id pub-id-type="pmid">25948538</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carta</surname><given-names>S</given-names></name><name><surname>Penco</surname><given-names>F</given-names></name><name><surname>Lavieri</surname><given-names>R</given-names></name><name><surname>Martini</surname><given-names>A</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Gattorno</surname><given-names>M</given-names></name><name><surname>Rubartelli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance</article-title><source>PNAS</source><volume>112</volume><fpage>2835</fpage><lpage>2840</lpage><pub-id pub-id-type="doi">10.1073/pnas.1424741112</pub-id><pub-id pub-id-type="pmid">25730877</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Lui</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Successful skeletal aging: a marker of low fracture risk and longevity</article-title><source>The Study of Osteoporotic Fractures (SOF). J Bone Miner Res</source><volume>24</volume><fpage>134</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1359/jbmr.080813</pub-id><pub-id pub-id-type="pmid">18715137</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cawthon</surname><given-names>PM</given-names></name><name><surname>Ewing</surname><given-names>SK</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Orwoll</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study</article-title><source>Journal of Bone and Mineral Research</source><volume>24</volume><fpage>1728</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1359/jbmr.090419</pub-id><pub-id pub-id-type="pmid">19419308</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cawthon</surname><given-names>PM</given-names></name><name><surname>Ewing</surname><given-names>SK</given-names></name><name><surname>Mackey</surname><given-names>DC</given-names></name><name><surname>Fink</surname><given-names>HA</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Stefanick</surname><given-names>ML</given-names></name><name><surname>Bauer</surname><given-names>DC</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Orwoll</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Change in hip bone mineral density and risk of subsequent fractures in older men</article-title><source>Journal of Bone and Mineral Research</source><volume>27</volume><fpage>2179</fpage><lpage>2188</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1671</pub-id><pub-id pub-id-type="pmid">22648990</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>RC</given-names></name><name><surname>Kouspou</surname><given-names>MM</given-names></name><name><surname>Lang</surname><given-names>BJ</given-names></name><name><surname>Nguyen</surname><given-names>CH</given-names></name><name><surname>van der Kraan</surname><given-names>AGJ</given-names></name><name><surname>Vieusseux</surname><given-names>JL</given-names></name><name><surname>Lim</surname><given-names>RC</given-names></name><name><surname>Gillespie</surname><given-names>MT</given-names></name><name><surname>Benjamin</surname><given-names>IJ</given-names></name><name><surname>Quinn</surname><given-names>JMW</given-names></name><name><surname>Price</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>13602</fpage><lpage>13614</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.530626</pub-id><pub-id pub-id-type="pmid">24692538</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Markman</surname><given-names>JL</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Crother</surname><given-names>TR</given-names></name><name><surname>Lane</surname><given-names>M</given-names></name><name><surname>Abolhesn</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>PK</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sex-specific effects of the nlrp3 inflammasome on atherogenesis in ldl receptor-deficient mice</article-title><source>JACC. Basic to Translational Science</source><volume>5</volume><fpage>582</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2020.03.016</pub-id><pub-id pub-id-type="pmid">32613145</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>M2b macrophages protect against doxorubicin induced cardiotoxicity via alternating autophagy in cardiomyocytes</article-title><source>PLOS ONE</source><volume>18</volume><elocation-id>e0288422</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0288422</pub-id><pub-id pub-id-type="pmid">37498828</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>RE</given-names></name><name><surname>Rathbone</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Management of cancer treatment-induced bone loss</article-title><source>Nature Reviews. Rheumatology</source><volume>9</volume><fpage>365</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2013.36</pub-id><pub-id pub-id-type="pmid">23507900</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eljack</surname><given-names>S</given-names></name><name><surname>Allard-Vannier</surname><given-names>E</given-names></name><name><surname>Misericordia</surname><given-names>Y</given-names></name><name><surname>Hervé-Aubert</surname><given-names>K</given-names></name><name><surname>Aubrey</surname><given-names>N</given-names></name><name><surname>Chourpa</surname><given-names>I</given-names></name><name><surname>Faggad</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Combination of nanovectorized sirna directed against survivin with doxorubicin for efficient anti-cancer activity in her2+ breast cancer cells</article-title><source>Pharmaceutics</source><volume>14</volume><elocation-id>2537</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14112537</pub-id><pub-id pub-id-type="pmid">36432729</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Georgiou</surname><given-names>KR</given-names></name><name><surname>Morris</surname><given-names>HA</given-names></name><name><surname>McKinnon</surname><given-names>RA</given-names></name><name><surname>Keefe</surname><given-names>DMK</given-names></name><name><surname>Howe</surname><given-names>PR</given-names></name><name><surname>Xian</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model</article-title><source>Breast Cancer Research and Treatment</source><volume>165</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s10549-017-4308-3</pub-id><pub-id pub-id-type="pmid">28550626</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>CM</given-names></name><name><surname>Su</surname><given-names>YW</given-names></name><name><surname>Howe</surname><given-names>PR</given-names></name><name><surname>Xian</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Long chain omega-3 polyunsaturated fatty acid supplementation protects against adriamycin and cyclophosphamide chemotherapy-induced bone marrow damage in female rats</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>484</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19020484</pub-id><pub-id pub-id-type="pmid">29415482</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldmann</surname><given-names>J</given-names></name><name><surname>Prieur</surname><given-names>A-M</given-names></name><name><surname>Quartier</surname><given-names>P</given-names></name><name><surname>Berquin</surname><given-names>P</given-names></name><name><surname>Certain</surname><given-names>S</given-names></name><name><surname>Cortis</surname><given-names>E</given-names></name><name><surname>Teillac-Hamel</surname><given-names>D</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>de Saint Basile</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes</article-title><source>American Journal of Human Genetics</source><volume>71</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1086/341357</pub-id><pub-id pub-id-type="pmid">12032915</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatti</surname><given-names>DM</given-names></name><name><surname>Weber</surname><given-names>SN</given-names></name><name><surname>Goodwin</surname><given-names>NC</given-names></name><name><surname>Lammert</surname><given-names>F</given-names></name><name><surname>Churchill</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic background influences susceptibility to chemotherapy-induced hematotoxicity</article-title><source>The Pharmacogenomics Journal</source><volume>18</volume><fpage>319</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/tpj.2017.23</pub-id><pub-id pub-id-type="pmid">28607509</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geffen</surname><given-names>DB</given-names></name><name><surname>Man</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>New drugs for the treatment of cancer, 1990-2001</article-title><source>The Israel Medical Association Journal</source><volume>4</volume><fpage>1124</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">12516906</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldshtein</surname><given-names>H</given-names></name><name><surname>Hausmann</surname><given-names>MJ</given-names></name><name><surname>Douvdevani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids</article-title><source>Annals of Clinical Biochemistry</source><volume>46</volume><fpage>488</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1258/acb.2009.009002</pub-id><pub-id pub-id-type="pmid">19729503</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Callaway</surname><given-names>JB</given-names></name><name><surname>Ting</surname><given-names>JPY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inflammasomes: mechanism of action, role in disease, and therapeutics</article-title><source>Nature Medicine</source><volume>21</volume><fpage>677</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/nm.3893</pub-id><pub-id pub-id-type="pmid">26121197</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>SD</given-names></name><name><surname>Giles</surname><given-names>HD</given-names></name><name><surname>Denine</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Antitumor drug toxicity in tumor-free and tumor-bearing mice</article-title><source>Cancer Chemotherapy and Pharmacology</source><volume>4</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1007/BF00254019</pub-id><pub-id pub-id-type="pmid">7397944</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Recent developments in combination chemotherapy for colorectal and breast cancers with topoisomerase inhibitors</article-title><source>International Journal of Molecular Sciences</source><volume>24</volume><elocation-id>8457</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24098457</pub-id><pub-id pub-id-type="pmid">37176164</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Ahn</surname><given-names>SM</given-names></name><name><surname>Oh</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Yoo</surname><given-names>B</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neutrophil extracellular trap clearance by synovial macrophages in gout</article-title><source>Arthritis Research &amp; Therapy</source><volume>23</volume><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.1186/s13075-021-02472-4</pub-id><pub-id pub-id-type="pmid">33741037</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karmakar</surname><given-names>M</given-names></name><name><surname>Katsnelson</surname><given-names>MA</given-names></name><name><surname>Dubyak</surname><given-names>GR</given-names></name><name><surname>Pearlman</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10555</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10555</pub-id><pub-id pub-id-type="pmid">26877061</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>D’Ovidio</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Palaniyar</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Anthracyclines suppress both nadph oxidase- dependent and -independent netosis in human neutrophils</article-title><source>Cancers</source><volume>11</volume><elocation-id>1328</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11091328</pub-id><pub-id pub-id-type="pmid">31500300</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komada</surname><given-names>T</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Platnich</surname><given-names>JM</given-names></name><name><surname>Beck</surname><given-names>PL</given-names></name><name><surname>Benediktsson</surname><given-names>H</given-names></name><name><surname>Duff</surname><given-names>HJ</given-names></name><name><surname>Jenne</surname><given-names>CN</given-names></name><name><surname>Muruve</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Macrophage uptake of necrotic cell dna activates the aim2 inflammasome to regulate a proinflammatory phenotype in ckd</article-title><source>Journal of the American Society of Nephrology</source><volume>29</volume><fpage>1165</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1681/ASN.2017080863</pub-id><pub-id pub-id-type="pmid">29439156</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells</article-title><source>Cancer Research</source><volume>48</volume><fpage>725</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">2825982</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Kwan</surname><given-names>K</given-names></name><name><surname>Levine</surname><given-names>YA</given-names></name><name><surname>Olofsson</surname><given-names>PS</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Chavan</surname><given-names>SS</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>α7 nicotinic acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release</article-title><source>Molecular Medicine</source><volume>20</volume><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.2119/molmed.2013.00117</pub-id><pub-id pub-id-type="pmid">24849809</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Long</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Simultaneous inhibition of breast cancer and its liver and lung metastasis by blocking inflammatory feed-forward loops</article-title><source>Journal of Controlled Release</source><volume>338</volume><fpage>662</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.08.047</pub-id><pub-id pub-id-type="pmid">34478751</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Fuss</surname><given-names>I</given-names></name><name><surname>Kitani</surname><given-names>A</given-names></name><name><surname>Strober</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses</article-title><source>Immunity</source><volume>30</volume><fpage>860</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.04.012</pub-id><pub-id pub-id-type="pmid">19501001</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>A</given-names></name><name><surname>Dreyling</surname><given-names>M</given-names></name><name><surname>Roeder</surname><given-names>F</given-names></name><name><surname>Baur-Melnyk</surname><given-names>A</given-names></name><name><surname>Knösel</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Birkenmaier</surname><given-names>C</given-names></name><name><surname>Jansson</surname><given-names>V</given-names></name><name><surname>Dürr</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Primary bone lymphoma: clinical presentation and therapeutic considerations</article-title><source>Journal of Bone Oncology</source><volume>25</volume><elocation-id>100326</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbo.2020.100326</pub-id><pub-id pub-id-type="pmid">33083218</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>D</given-names></name><name><surname>Shida</surname><given-names>H</given-names></name><name><surname>Kusunoki</surname><given-names>Y</given-names></name><name><surname>Miyoshi</surname><given-names>A</given-names></name><name><surname>Nishio</surname><given-names>S</given-names></name><name><surname>Tomaru</surname><given-names>U</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Ishizu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The responses of macrophages in interaction with neutrophils that undergo netosis</article-title><source>Journal of Autoimmunity</source><volume>67</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2015.08.018</pub-id><pub-id pub-id-type="pmid">26347075</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Yoon</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>JN</given-names></name><name><surname>Suh</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Doxorubicin induces bone loss by increasing autophagy through a mitochondrial ros/trpml1/tfeb axis in osteoclasts</article-title><source>Antioxidant</source><volume>11</volume><elocation-id>1476</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11081476</pub-id><pub-id pub-id-type="pmid">36009195</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Bonar</surname><given-names>SL</given-names></name><name><surname>Hickman-Brecks</surname><given-names>CL</given-names></name><name><surname>Abu-Amer</surname><given-names>S</given-names></name><name><surname>McGeough</surname><given-names>MD</given-names></name><name><surname>Peña</surname><given-names>CA</given-names></name><name><surname>Broderick</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Grimston</surname><given-names>SK</given-names></name><name><surname>Kading</surname><given-names>J</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Novack</surname><given-names>DV</given-names></name><name><surname>Hoffman</surname><given-names>HM</given-names></name><name><surname>Civitelli</surname><given-names>R</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms</article-title><source>FASEB Journal</source><volume>29</volume><fpage>1269</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1096/fj.14-264804</pub-id><pub-id pub-id-type="pmid">25477279</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rana</surname><given-names>T</given-names></name><name><surname>Chakrabarti</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e78043</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0078043</pub-id><pub-id pub-id-type="pmid">24205081</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinam</surname><given-names>VAK</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Waggoner</surname><given-names>SN</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>LE</given-names></name><name><surname>Waggoner</surname><given-names>L</given-names></name><name><surname>Vanaja</surname><given-names>SK</given-names></name><name><surname>Monks</surname><given-names>BG</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Vogel</surname><given-names>SN</given-names></name><name><surname>Szomolanyi-Tsuda</surname><given-names>E</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses</article-title><source>Nature Immunology</source><volume>11</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/ni.1864</pub-id><pub-id pub-id-type="pmid">20351692</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>CN</given-names></name><name><surname>Hoban</surname><given-names>PR</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines</article-title><source>Cancer Research</source><volume>47</volume><fpage>1560</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">2434220</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>HA</given-names></name><name><surname>Ramdan</surname><given-names>E</given-names></name><name><surname>Elmazar</surname><given-names>MM</given-names></name><name><surname>Azzazy</surname><given-names>HME</given-names></name><name><surname>Abdelnaser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comparing the protective effects of resveratrol, curcumin and sulforaphane against LPS/IFN-γ-mediated inflammation in doxorubicin-treated macrophages</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>545</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-80804-1</pub-id><pub-id pub-id-type="pmid">33436962</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>SAtutza</surname><given-names>A</given-names></name><name><surname>Horvath</surname><given-names>GL</given-names></name><name><surname>Monks</surname><given-names>BG</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ASC speck formation as a readout for inflammasome activation</article-title><source>Methods in Molecular Biology</source><volume>1040</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-523-1</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>BR</given-names></name><name><surname>Kanneganti</surname><given-names>T-D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NLRP3 inflammasome in cancer and metabolic diseases</article-title><source>Nature Immunology</source><volume>22</volume><fpage>550</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00886-5</pub-id><pub-id pub-id-type="pmid">33707781</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Crother</surname><given-names>TR</given-names></name><name><surname>Karlin</surname><given-names>J</given-names></name><name><surname>Dagvadorj</surname><given-names>J</given-names></name><name><surname>Chiba</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ramanujan</surname><given-names>VK</given-names></name><name><surname>Wolf</surname><given-names>AJ</given-names></name><name><surname>Vergnes</surname><given-names>L</given-names></name><name><surname>Ojcius</surname><given-names>DM</given-names></name><name><surname>Rentsendorj</surname><given-names>A</given-names></name><name><surname>Vargas</surname><given-names>M</given-names></name><name><surname>Guerrero</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Underhill</surname><given-names>DM</given-names></name><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis</article-title><source>Immunity</source><volume>36</volume><fpage>401</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.01.009</pub-id><pub-id pub-id-type="pmid">22342844</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LA</given-names></name><name><surname>Cornelius</surname><given-names>VR</given-names></name><name><surname>Plummer</surname><given-names>CJ</given-names></name><name><surname>Levitt</surname><given-names>G</given-names></name><name><surname>Verrill</surname><given-names>M</given-names></name><name><surname>Canney</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials</article-title><source>BMC Cancer</source><volume>10</volume><elocation-id>337</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-10-337</pub-id><pub-id pub-id-type="pmid">20587042</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snouwaert</surname><given-names>JN</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Repenning</surname><given-names>PW</given-names></name><name><surname>Dye</surname><given-names>R</given-names></name><name><surname>Livingston</surname><given-names>EW</given-names></name><name><surname>Kovarova</surname><given-names>M</given-names></name><name><surname>Moy</surname><given-names>SS</given-names></name><name><surname>Brigman</surname><given-names>BE</given-names></name><name><surname>Bateman</surname><given-names>TA</given-names></name><name><surname>Ting</surname><given-names>JPY</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An nlrp3 mutation causes arthropathy and osteoporosis in humanized mice</article-title><source>Cell Reports</source><volume>17</volume><fpage>3077</fpage><lpage>3088</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.052</pub-id><pub-id pub-id-type="pmid">27974218</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway</article-title><source>Science</source><volume>339</volume><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1126/science.1232458</pub-id><pub-id pub-id-type="pmid">23258413</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Brodt</surname><given-names>MD</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Alippe</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Hao</surname><given-names>D</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Silva</surname><given-names>MJ</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Fracture healing is delayed in the absence of gasdermin-interleukin-1 signaling</article-title><source>eLife</source><volume>11</volume><elocation-id>e75753</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.75753</pub-id><pub-id pub-id-type="pmid">35244027</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svendsen</surname><given-names>P</given-names></name><name><surname>Shekhrajka</surname><given-names>N</given-names></name><name><surname>Nielsen</surname><given-names>KL</given-names></name><name><surname>Vestergaard</surname><given-names>P</given-names></name><name><surname>Poulsen</surname><given-names>MØ</given-names></name><name><surname>Vistisen</surname><given-names>AK</given-names></name><name><surname>Munksgaard</surname><given-names>PS</given-names></name><name><surname>Severinsen</surname><given-names>MT</given-names></name><name><surname>Jensen</surname><given-names>P</given-names></name><name><surname>Johnsen</surname><given-names>HE</given-names></name><name><surname>Jakobsen</surname><given-names>LH</given-names></name><name><surname>Bøgsted</surname><given-names>M</given-names></name><name><surname>Frøkjær</surname><given-names>JB</given-names></name><name><surname>El-Galaly</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients</article-title><source>Leukemia &amp; Lymphoma</source><volume>58</volume><fpage>1105</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1080/10428194.2016.1233543</pub-id><pub-id pub-id-type="pmid">27736260</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacar</surname><given-names>O</given-names></name><name><surname>Sriamornsak</surname><given-names>P</given-names></name><name><surname>Dass</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems</article-title><source>The Journal of Pharmacy and Pharmacology</source><volume>65</volume><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2012.01567.x</pub-id><pub-id pub-id-type="pmid">23278683</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeshita</surname><given-names>S</given-names></name><name><surname>Kaji</surname><given-names>K</given-names></name><name><surname>Kudo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts</article-title><source>Journal of Bone and Mineral Research</source><volume>15</volume><fpage>1477</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2000.15.8.1477</pub-id><pub-id pub-id-type="pmid">10934646</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tewey</surname><given-names>KM</given-names></name><name><surname>Rowe</surname><given-names>TC</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Halligan</surname><given-names>BD</given-names></name><name><surname>Liu</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II</article-title><source>Science</source><volume>226</volume><fpage>466</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1126/science.6093249</pub-id><pub-id pub-id-type="pmid">6093249</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villalba-Campos</surname><given-names>M</given-names></name><name><surname>Ramírez-Clavijo</surname><given-names>SR</given-names></name><name><surname>Sánchez-Corredor</surname><given-names>MC</given-names></name><name><surname>Rondón-Lagos</surname><given-names>M</given-names></name><name><surname>Ibáñez-Pinilla</surname><given-names>M</given-names></name><name><surname>Palma</surname><given-names>RM</given-names></name><name><surname>Varona-Uribe</surname><given-names>ME</given-names></name><name><surname>Chuaire-Noack</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Quantification of cell-free DNA for evaluating genotoxic damage from occupational exposure to car paints</article-title><source>Journal of Occupational Medicine and Toxicology</source><volume>11</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1186/s12995-016-0123-8</pub-id><pub-id pub-id-type="pmid">27429640</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Katz</surname><given-names>D</given-names></name><name><surname>Araujo</surname><given-names>DM</given-names></name><name><surname>Ravi</surname><given-names>V</given-names></name><name><surname>Ludwig</surname><given-names>JA</given-names></name><name><surname>Trent</surname><given-names>JC</given-names></name><name><surname>Patel</surname><given-names>SR</given-names></name><name><surname>Lin</surname><given-names>PP</given-names></name><name><surname>Guadagnolo</surname><given-names>A</given-names></name><name><surname>Lòpez-Terrada</surname><given-names>D</given-names></name><name><surname>Dei Tos</surname><given-names>AP</given-names></name><name><surname>Lewis</surname><given-names>VO</given-names></name><name><surname>Lev</surname><given-names>D</given-names></name><name><surname>Pollock</surname><given-names>RE</given-names></name><name><surname>Zagars</surname><given-names>GK</given-names></name><name><surname>Benjamin</surname><given-names>RS</given-names></name><name><surname>Madewell</surname><given-names>JE</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy</article-title><source>Clinical Sarcoma Research</source><volume>2</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/2045-3329-2-25</pub-id><pub-id pub-id-type="pmid">23272660</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>CX</given-names></name><name><surname>Alippe</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Schipani</surname><given-names>E</given-names></name><name><surname>Civitelli</surname><given-names>R</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Chronic inflammation triggered by the NLRP3 inflammasome in myeloid cells promotes growth plate dysplasia by mesenchymal cells</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>4880</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-05033-5</pub-id><pub-id pub-id-type="pmid">28687790</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Hockerman</surname><given-names>S</given-names></name><name><surname>Jacobsen</surname><given-names>EJ</given-names></name><name><surname>Alippe</surname><given-names>Y</given-names></name><name><surname>Selness</surname><given-names>SR</given-names></name><name><surname>Hope</surname><given-names>HR</given-names></name><name><surname>Hirsch</surname><given-names>JL</given-names></name><name><surname>Mnich</surname><given-names>SJ</given-names></name><name><surname>Saabye</surname><given-names>MJ</given-names></name><name><surname>Hood</surname><given-names>WF</given-names></name><name><surname>Bonar</surname><given-names>SL</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Haimovich</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>HM</given-names></name><name><surname>Monahan</surname><given-names>JB</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>1315</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1084/jem.20172063</pub-id><pub-id pub-id-type="pmid">29549113</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Nowak</surname><given-names>K</given-names></name><name><surname>Gunasekera</surname><given-names>K</given-names></name><name><surname>Alippe</surname><given-names>Y</given-names></name><name><surname>Speckman</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Kress</surname><given-names>D</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Parp1 hinders histone h2b occupancy at the nfatc1 promoter to restrain osteoclast differentiation</article-title><source>Journal of Bone and Mineral Research</source><volume>35</volume><fpage>776</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3927</pub-id><pub-id pub-id-type="pmid">31793068</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Alippe</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name><name><surname>Monahan</surname><given-names>JB</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NLRP3 inflammasome activation triggers gasdermin D-independent inflammation</article-title><source>Science Immunology</source><volume>6</volume><elocation-id>eabj3859</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abj3859</pub-id><pub-id pub-id-type="pmid">34678046</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittenburg</surname><given-names>LA</given-names></name><name><surname>Weishaar</surname><given-names>K</given-names></name><name><surname>Ramirez</surname><given-names>D</given-names></name><name><surname>Gustafson</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers</article-title><source>Veterinary and Comparative Oncology</source><volume>17</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1111/vco.12455</pub-id><pub-id pub-id-type="pmid">30638304</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>H</given-names></name><name><surname>Watari</surname><given-names>K</given-names></name><name><surname>Sanchez-Lopez</surname><given-names>E</given-names></name><name><surname>Offenberger</surname><given-names>J</given-names></name><name><surname>Onyuru</surname><given-names>J</given-names></name><name><surname>Sampath</surname><given-names>H</given-names></name><name><surname>Ying</surname><given-names>W</given-names></name><name><surname>Hoffman</surname><given-names>HM</given-names></name><name><surname>Shadel</surname><given-names>GS</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signaling</article-title><source>Immunity</source><volume>55</volume><fpage>1370</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.06.007</pub-id><pub-id pub-id-type="pmid">35835107</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>JC</given-names></name><name><surname>Alippe</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Kress</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Kostecki</surname><given-names>KL</given-names></name><name><surname>Monahan</surname><given-names>JB</given-names></name><name><surname>Veis</surname><given-names>DJ</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Link</surname><given-names>DC</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Radiation causes tissue damage by dysregulating inflammasome-gasdermin D signaling in both host and transplanted cells</article-title><source>PLOS Biology</source><volume>18</volume><elocation-id>e3000807</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000807</pub-id><pub-id pub-id-type="pmid">32760056</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CA</given-names></name><name><surname>Huang</surname><given-names>ST</given-names></name><name><surname>Chiang</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages</article-title><source>Rheumatology</source><volume>54</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keu318</pub-id><pub-id pub-id-type="pmid">25161312</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Murali</surname><given-names>B</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Faget</surname><given-names>DV</given-names></name><name><surname>Cole</surname><given-names>T</given-names></name><name><surname>Ricci</surname><given-names>B</given-names></name><name><surname>Thotala</surname><given-names>D</given-names></name><name><surname>Monahan</surname><given-names>J</given-names></name><name><surname>van Deursen</surname><given-names>JM</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Faccio</surname><given-names>R</given-names></name><name><surname>Schwarz</surname><given-names>JK</given-names></name><name><surname>Stewart</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Therapy-induced senescence drives bone loss</article-title><source>Cancer Research</source><volume>80</volume><fpage>1171</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-2348</pub-id><pub-id pub-id-type="pmid">31932453</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youm</surname><given-names>YH</given-names></name><name><surname>Grant</surname><given-names>RW</given-names></name><name><surname>McCabe</surname><given-names>LR</given-names></name><name><surname>Albarado</surname><given-names>DC</given-names></name><name><surname>Nguyen</surname><given-names>KY</given-names></name><name><surname>Ravussin</surname><given-names>A</given-names></name><name><surname>Pistell</surname><given-names>P</given-names></name><name><surname>Newman</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Laque</surname><given-names>A</given-names></name><name><surname>Münzberg</surname><given-names>H</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Ingram</surname><given-names>DK</given-names></name><name><surname>Salbaum</surname><given-names>JM</given-names></name><name><surname>Dixit</surname><given-names>VD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging</article-title><source>Cell Metabolism</source><volume>18</volume><fpage>519</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.09.010</pub-id><pub-id pub-id-type="pmid">24093676</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Brautigam</surname><given-names>CA</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop</article-title><source>Cell Reports</source><volume>6</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.01.003</pub-id><pub-id pub-id-type="pmid">24462292</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Kuai</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Doxorubicin restrains osteogenesis and promotes osteoclastogenesis in vitro</article-title><source>American Journal of Translational Research</source><volume>12</volume><fpage>5640</fpage><lpage>5654</lpage><pub-id pub-id-type="pmid">33042445</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimny</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Mechanoreceptors in articular tissues</article-title><source>The American Journal of Anatomy</source><volume>182</volume><fpage>16</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/aja.1001820103</pub-id><pub-id pub-id-type="pmid">3291597</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92885.4.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Weigel</surname><given-names>Detlef</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Max Planck Institute for Biology Tübingen</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>This <bold>useful</bold> study, which systematically addresses off-target effects of a commonly used chemotherapy drug on bone and bone marrow cells and which therefore is of potential interest to a broad readership, presents evidence that reducing systemic inflammation induced by doxorubicin limits bone loss to some extent. The demonstration of the effect of systemic inflammation on bone loss is <bold>convincing</bold>. Building on prior work, this study sets the scene for additional genetic and pharmacologic experiments as well as future analyses of the bone phenotypes, which should speak to the mechanisms involved in doxorubicin-induced bone loss – which are not addressed in the current study – and which may substantiate the clinical relevance of targeting inflammation in order to limit the negative impact of chemotherapies on bone quality.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92885.4.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Doxorubincin has long been known to cause bone loss by increasing osteoclast and suppressing osteoblast activities. The study by Wang et al. reports a comprehensive investigation into the off-target effects of doxorubicin on bone tissues and potential mechanisms.. They used a tumor-free model with wild type mice and found that even a single dose of doxorubicin has a major influence by increasing leukopenia and DAMPs and inflammasomes in macrophages and neutrophils, and inflammation-related cell death (pyroptosis and NETosis). The gene knockout study shows that AIM2 and NLRP3 are the major contributors to bone loss. Overall, the study confirmed previous findings regarding the impact of doxorubicin on tissue inflammation and expands the research further into bone tissue. The presented data presented are consistent; however, a major question remains regarding whether doxorubicin drives inflammation and its related events. Most in vitro study showed that the effect of doxorubincin cannot be demonstrated without LPS priming. This observation raises the question of whether doxorubincin itself could activate the inflammasome and the related events. In vivo study, on the other hand, suggested that it doesn't require LPS. The inconsistency here was not explained further. Moreover, a tumor-free mouse model was used for the study; however, immune responses in tumor bearing models would likely be distinct from tumor-free ones. The justification for using tumor-free models is not well-established.</p><p>Strengths:</p><p>The paper includes a comprehensive study that shows the effects of doxorubincin on cytokine levels in serum, release of DAMPs and NETosis, and leukopenia using both in vivo and in vitro models. Bone marrow cells, macrophages and neutrophils were isolated from the bone marrow, and the levels of cytokines in serum were also determined.</p><p>They employed multiple knockout models with deficiency in Aim 2, Nlirp3, and double deficiencies to dissect the functional involvement of these two inflammasomes.</p><p>The experiments in general are well designed. The paper is also logically written, and figures were clearly labeled.</p><p>Weaknesses:</p><p>Most of the data presented are correlative, and there is not much effort to dissect the underlying molecular mechanism.</p><p>It is not entirely clear why a tumor free model is chosen to study immune responses, as immune responses can differ significantly with or without tumor-bearing.</p><p>Immune responses in isolated macrophages, neutrophils and bone marrow cells require priming with LPS, while such responses are not observed in vivo. There is no explanation for these differences.</p><p>The band intensities on Western blots in Fig. 4 and Fig. 5 are not quantified, and the numbers of repeats are also not provided.</p><p>Many abbreviations are used throughout the text, and some of the full names are not provided.</p><p>Fig. 5B needs a label on X axis.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92885.4.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Wang and collaborators have evaluated the impact of inflammation on bone loss induced by Doxorubicin, which is commonly used in chemotherapy to treat various cancers. In mice, they show that a single injection of Doxorubicin induces systemic inflammation, leukopenia, and a significant bone loss associated with increased bone-resorbing osteoclast numbers. In vitro, the authors show that Doxorubicin activates the AIM2 and NLRP3 inflammasomes in macrophages and neutrophils. Importantly, they show that the full knockouts (germline deletions) of AIM2 (Aim2-/-) and NLRP3 (Nlrp3-/-) and Caspase 1 (Casp1-/-) limit (but do not completely abolish) bone loss induced 4 weeks after a single injection of Doxorubicin in mice. From these results, they conclude that Doxorubicin activates inflammasomes to cause inflammation-associated bone loss.</p><p>Strength:</p><p>This manuscript provides functional experiments demonstrating that NRLP3 and/or AIM2 loss-of-functions (and thus the systemic impairment of the inflammatory response) prevent bone-loss induced by Doxorubicin in mice.</p><p>Weaknesses:</p><p>Numerous studies have reported that Doxorubicin induces systemic inflammation and activates the inflammasome in myeloid cells and various other cell types. It is also known that systemic inflammation and Doxorubicin treatment lead to bone loss. Hence, the key conclusions drawn from this work have been known already or were very much expected. Therefore, the novelty appears somewhat limited. One important limitation is the lack of experiments that could determine which cell lineages are involved in bone loss induced by Doxorubicin in vivo, while the tools to do so exist. The characterization of the bone phenotype is incomplete, and unfortunately does not tell us whether the inflammasome is activated in some of the cell lineages present in bones in vivo. Another limitation is that the relative importance of the inflammasomes compared to cell senescence and autophagy, which are also induced by Doxorubicin, has not been evaluated. Hence the main molecular mechanisms responsible for bone loss induced by Doxorubicin in vivo remains unknown. Lastly, it would have been interesting, on a more clinical point of view, to compare the few relevant treatments that could limit the deleterious effect of Doxorubicin on bone loss while preserving the toxicity on tumor cells.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92885.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chun</given-names></name><role specific-use="author">Author</role><aff><institution>Washington University School of Medicine</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>Khushpreet</given-names></name><role specific-use="author">Author</role><aff><institution>Washington University School of Medicine</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Canxin</given-names></name><role specific-use="author">Author</role><aff><institution>Aclaris Therapeutics, Inc.</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Abu-Amer</surname><given-names>Yousef</given-names></name><role specific-use="author">Author</role><aff><institution>Washington University in St. Louis</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Mbalaviele</surname><given-names>Gabriel</given-names></name><role specific-use="author">Author</role><aff><institution>Washington University School of Medicine</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewing Editor</bold></p><p>We thank you for clarifying several of the questions raised by the reviewers. Since the study has otherwise largely stayed unchanged, we will leave the eLife assessment as “before”:</p></disp-quote><p>We respectfully disagree because we addressed all concerns raised by the two reviewers except one (below), which was not satisfactorily answered according to reviewer 1; it has now been addressed (new S3 Fig).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>The authors addressed most of my previous comments. However, there is one important point that was not satisfactorily addressed &quot;The band intensities on Western blots in Fig. 4 and Fig. 5 are not quantified, and the numbers of repeats are also not provided&quot; The response that &quot;It is not straightforward to quantify and describe the intensity of the bands of these numerous with different fate outcomes.&quot; In the revision, they mentioned at least three repeats were performed. If so, it's not entirely clear why they couldn't quantify the western blots results. Including quantitative data will strengthen the rigor of the findings.</p></disp-quote><p>Quantitative data from Fig. 4 and Fig. 5 are now provided as S3 Fig and described in the manuscript (lines 170-175; 184-188).</p></body></sub-article></article>